Associate Professor of Clinical Pediatrics-CHLA Division of Hematology OncologyApply (https://facultypositions.usc.edu/FAS/application/position?postingId=REQ20114930) Keck School of Medicine Faculty Los Angeles, California

The University of Southern California (USC), founded in 1880, is the largest private employer in the City of Los Angeles. As an employee of USC, you will be a part of a world-class research university and a member of the "Trojan Family," which is comprised of the faculty, students and staff that make the university what it is.

Medical Director of Hematology

Hematology Section, Division of Hematology-Oncology, Cancer and Blood Disease Institute

Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California

The Keck School of Medicine (KSOM) of the University of Southern California (USC) and Children’s Hospital Los Angeles (CHLA) are actively seeking a full-time faculty member for the position of Medical Director of Hematology within the Division of Hematology-Oncology and the Cancer and Blood Disease Institute (CBDI). The successful candidate will hold a primary academic appointment in the Department of Pediatrics at the University of Southern California (USC) Keck School of Medicine at the level of Associate Professor.

In this position, he/she is expected to serve as the Medical Director of the Hematology service. The candidate must have a clinical focus in non-malignant hematology and particular expertise in clinical practice systems organization with the ability to effectively and efficiently use informatics and data analytics to streamline patient flow, optimize reimbursement, improve quality of care, improve operations, and promote continual systems and quality improvement. The successful candidate will work closely with the hematology team, the Division, and CHLA administration to develop the vision for improvement of efficiency of clinical and academic practices. An academic interest in clinical systems and quality improvement would be favored. This position will involve clinical practice in non-malignant hematology as well as clinical, academic (research and/or education), and administrative responsibilities.

The Division and CBDI have an internationally renowned team of medical professionals who use an interdisciplinary approach to treat children with blood disorders and who work continually to make advances in treating blood diseases. The focus of the Hematology Section is diagnosis, management and research for nonmalignant blood disorders. Physicians, nurse practitioners, clinical nurses, social workers and other caregivers offer our patients and their families special expertise, counseling and education in health maintenance, nutrition, and pain management. The Hematology Section currently treats approximately 1800 patients annually with a wide variety of blood disorders. The hematology team providers are recognized for their range of clinical, teaching, research, and clinical trial achievements. The team focuses on genetic diseases that start at birth, some of which are quite rare. They partner with families to care for their children and work with adult providers to assure continued state of the art management and special expertise for patients of all ages with rare genetic blood diseases. The Hematology Section includes the following specialized programs: general hematology; hemostasis and thrombosis; sickle cell disease, thalassemia, and other red blood cell disorders; bone marrow failure; iron overload; white blood cell disorders; epidermolysis bullosa; clinical trials including gene therapy; and medical care transition

The CBDI is the largest and top-ranked pediatric hematology-oncology program in the western U.S. TheU.S. News & World Reportranked the CBDI #7 and CHLA #5 in the nation in 2021-2022. The CBDI has a large clinical trials operation that supports programs in hematology, oncology, and transplantation/cellular therapy. Three leading, international clinical trials consortia are headquartered within the CBDI: Children's Hospital-Acquired Thrombosis (CHAT); Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL); and New Approaches to Neuroblastoma Therapy (NANT). The CBDI is an active member of additional leading consortia including the North American Pediatric Aplastic Anemia Consortium (NAPAAC). CBDI investigators conduct extensive bench-to-bedside research with research funding in FY21 totaling $55 million with $12 million in new awards. The Institute’s hematology investigators are conducting pioneering research into the measurement and management of iron overload, the basic pathology of sickle cell disease, and the treatment of childhood bleeding and clotting disorders.

The CBDI hosts an ACGME-accredited pediatric hematology-oncology fellowship training program and 1-year advanced subspecialty fellowships in Coagulation, Transplantation/Cellular Therapy, Neuro-Oncology, and AYA Oncology.

Administrative and research support including staff, resources and infrastructure will be provided. CHLA and USC are equal opportunity, affirmative action employers. The division greatly values diversity and is committed to building a vibrant and culturally diverse community of faculty that best reflects the patients and families we serve. Individuals from underrepresented groups in medicine are especially encouraged to apply.

Apply here and for further inquiries contact:

Thomas D. Coates, MD

Section Head, Hematology

Division of Hematology-Oncology

Cancer and Blood Disease Institute

Children’s Hospital Los Angeles

Professor of Pediatrics and Pathology

Keck School of Medicine

University of Southern California

Email:tcoates@chla.usc.edu

REQ20114930 Posted Date: 03/28/2022